Evotec looks to recover payments from Andromeda over faked Phase III data

By Dan Stanton

- Last updated on GMT

Data-faking Andromeda in legal trouble with Evotec over milestone
Evotec has taken legal action to recover €3.4m ($4.4m) in milestone payments from Andromeda Biotech which was found to have faked data in a Phase III trial.

Earlier this month, California-based Hyperion Therapeutics terminated the development of its Type 1 diabetes candidate DiaPep277​ after it discovered trial data had been manipulated by employees of Andromeda, an Israeli firm it acquired in June for $20m.

Hyperion’s CEO Donald Santel said he was “shocked and disheartened”​ at the serious misconduct and would be exploring its legal options against Andromeda and its former owners Clal Biotechnology Industry.

However, Hyperion is not the only firm to have suffered financial loss as today contract research organisation Evotec announced it would be taking legal steps against to recover all “claims and potential damages that result from recent incidents in relation to DiaPep277.”

DiaPep277 was initially developed by DeveloGen who sold all rights to the candidate to Andromeda in 2007. Three years later, fellow Germany-based firm Evotec acquired DeveloGen along with the rights for single-digit royalty rates and certain milestones for the development and commercialisation of DiaPep277.

Evotec’s CEO Dr Werner Lanthaler told this publication it was entitled to €3.4m from Andromeda in milestone payments, following the completion of the DIA-AID Phase III trial, which was the first trial where data was found to have been manipulated by Andromeda employees and a third-party biologistics firm.

“We are entitled to this as the trial was completed, independent to whether or not the data was faked,”​ he explained. “Unfortunately in this case it was, which was something no one could have ever expected.”

He continued, adding Evotec was taking legal action to both maximise its claim and to ensure Andromeda was penalized somewhat over this serious misdemeanour. “We definitely can’t let this go morally, [and] Andromeda has to be brought to justice.”

Lanthaler confirmed Evotec has been in talks with Hyperion over the situation.

Evotec had not been involved in the development of DiaPep277, while its subsidiary DeveloGen was not involved past 2007 and played no part in the data-fixing actions that led to the candidate’s termination.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars